Wellington Management Group
ABUS icon

Wellington Management Group’s Arbutus Biopharma ABUS Stock Holding History

Wellington Management Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Buy
461,646
+20,722
+5% +$91K ﹤0.01% 1606
2026
Q1 		$1.98M Sell
440,924
-33,437
-7% -$146K ﹤0.01% 1551
2025
Q4 		$2.28M Sell
474,361
-39,722
-8% -$179K ﹤0.01% 1569
2025
Q3 		$2.33M Sell
514,083
-17,468
-3% -$64.2K ﹤0.01% 1594
2025
Q2 		$1.64M Buy
531,551
+21,042
+4% +$69.9K ﹤0.01% 1622
2025
Q1 		$1.78M Sell
510,509
-2,793
-0.5% -$9.31K ﹤0.01% 1588
2024
Q4 		$1.68M Buy
513,302
+16,484
+3% +$60.6K ﹤0.01% 1611
2024
Q3 		$1.91M Buy
496,818
+21,807
+5% +$83.6K ﹤0.01% 1550
2024
Q2 		$1.47M Buy
475,011
+23,706
+5% +$71.1K ﹤0.01% 1584
2024
Q1 		$1.16M Buy
+451,305
New +$1.17M ﹤0.01% 1652
2023
Q2 		– Sell
-279,832
Closed -$848K – 1796
2023
Q1 		$848K Sell
279,832
-129,672
-32% -$366K ﹤0.01% 1699
2022
Q4 		$954K Sell
409,504
-24,060
-6% -$57.6K ﹤0.01% 1640
2022
Q3 		$828K Sell
433,564
-71,700
-14% -$169K ﹤0.01% 1693
2022
Q2 		$1.37M Hold
505,264
– – ﹤0.01% 1612
2022
Q1 		$1.51M Buy
505,264
+225,175
+80% +$689K ﹤0.01% 1658
2021
Q4 		$1.09M Buy
+280,089
New +$1.09M ﹤0.01% 1787

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wellington Management Group's ABUS Position: Q2 2026 in Review

Wellington Management Group increased its Arbutus Biopharma (ABUS) stake by 4.7% in Q2 2026, buying an estimated $91K and bringing the position to 461,646 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

Wellington Management Group first reported a position in ABUS in Q4 2021 and has held it in 16 quarters since. The position peaked at $2.33M in Q3 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Wellington Management Group held 461,646 shares of Arbutus Biopharma worth $2.22M as of Q2 2026.
  • Wellington Management Group bought 20,722 Arbutus Biopharma shares in Q2 2026, an estimated $91K.
  • Arbutus Biopharma made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1606 holding.
  • Wellington Management Group first reported a position in Arbutus Biopharma in Q4 2021 and has held it in 16 quarters since.
  • Wellington Management Group's Arbutus Biopharma position peaked at $2.33M in Q3 2025.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.